In study, we investigated the effect of treatment with combination of < 3 kDa + Rg1 on scopolamine-induced cognitive impairment in mice and the mechanism of BDNF/TrKB/CREB signaling pathway in PC12 cells is regulated. In behavioral experiments, < 3 kDa+Rg1 treatment improved the memorizing ability of mice. Treatment with < 3 kDa+Rg1 significantly regulated the function of neurotransmitters and effectively improved the morphology of the neurons determined by H&E, Nissl, and Golgi staining. Additionally, immunohistochemistry showed that the < 3 kDa+Rg1 treatment significantly decreased AChE activity and increased ChAT content in the hippocampus. The treatment upregulated VAChT, activated the BDNF/TrKB/CREB signaling pathway, improved the remodeling of dendritic spines, and enhanced cholinergic functions. In the scopolamine-induced PC12 cells, combination treatment increased Trx-1 expression after administering TrKB and activated signaling pathway. The results showed combination of < 3 kDa+Rg1 activated the BDNF/TrKB/CREB signaling pathway by regulating function of neurotransmitters and enhanced cholinergic function to decrease cognitive impairment.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: